As the U.S. flu season winds down, health officials say the flu vaccine didn’t work very well. It had one of its worst effectiveness rates in more than a decade.

Viral mismatch between circulating strains and vaccine may have weighed down effectiveness ...

The U.S. Food and Drug Administration (FDA) recently informed Moderna that it would not review the company’s application for approval of its new flu vaccine, which is its first using mRNA technology ...

As flu cases are surging across the United States, here's what to know about whether or not you can still get the vaccine.

FDA advisers recommend fall flu shot changes to include the new subclade K H3N2 variant for the 2026-27 season, improving vaccine relevance.

Incentives to bring vaccines to market are shrinking. Drugmakers are scaling back research investments and cutting jobs.

While current flu shots need to be updated each season, scientists are finding new ways to make vaccine that could last much longer and cover more strains.

Moderna said the Food and Drug Administration has agreed to review its experimental mRNA flu shot, reversing an earlier decision to refuse to accept the application. The FDA is slated to make a ...

The University of North Dakota is in the "home stretch" as influenza cases wind down, according to UND's medical director of Student Health Services. Laura Morgan said UND ...

Add Yahoo as a preferred source to see more of our stories on Google. The U.S. Food and Drug Administration (FDA) recently informed Moderna that it would not review the company’s application for ...